Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 19/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184258 | 1.00 | PTPN11 (0.36) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL29595742 | 0.83 | PTPN11 (0.50) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL18328573 | 0.83 | PTPN11 (0.36) | PTPN11KCNH2 | |
| SCHEMBL18319495 | 0.83 | PTPN11 (0.50) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL18319878 | 0.81 | KMT2A (0.33) | — | |
| SCHEMBL22792872 | 0.80 | PTPN11 (0.43) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL22792843 | 0.80 | PTPN11 (0.36) | PTPN11KCNH2 | |
| SCHEMBL28512238 | 0.79 | PTPN11 (0.39) | PTPN11MAPK1 | |
| SCHEMBL23901633 | 0.79 | PTPN11 (0.39) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL29930669 | 0.79 | PTPN11 (0.39) | PTPN11KCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625028-A | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3310774-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | PTPN11 12/4885KCNH2 3266/4885MAPK3 120/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | PTPN11 12/4885KCNH2 3261/4885MAPK3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.